Bio Cardia, Inc. BCDA
We take great care to ensure that the data presented and summarized in this overview for BioCardia, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BCDA
Top Purchases
Top Sells
About BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Insider Transactions at BCDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
900
+0.33%
|
$900
$1.3 P/Share
|
|
Dec 16
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
200
+0.07%
|
$200
$1.37 P/Share
|
|
Dec 08
2025
|
Edward M Gillis Senior Vice President, Devices |
BUY
Payment of exercise price or tax liability
|
Direct |
15,172
+32.25%
|
$15,172
$1.37 P/Share
|
|
Dec 08
2025
|
Edward M Gillis Senior Vice President, Devices |
BUY
Grant, award, or other acquisition
|
Direct |
38,078
+44.73%
|
$38,078
$1.37 P/Share
|
|
Dec 08
2025
|
David Mc Clung Chief Financial Officer |
BUY
Payment of exercise price or tax liability
|
Direct |
29,339
+27.62%
|
$29,339
$1.37 P/Share
|
|
Dec 08
2025
|
David Mc Clung Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,276
+35.43%
|
$58,276
$1.37 P/Share
|
|
Dec 08
2025
|
Peter Altman President and CEO |
BUY
Payment of exercise price or tax liability
|
Direct |
56,484
+17.47%
|
$56,484
$1.37 P/Share
|
|
Dec 08
2025
|
Peter Altman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
106,588
+24.79%
|
$106,588
$1.37 P/Share
|
|
Sep 19
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
48,000
+18.13%
|
$48,000
$1.25 P/Share
|
|
Sep 19
2025
|
Andrew Scott Blank Director |
BUY
Open market or private purchase
|
Indirect |
288,000
+31.24%
|
$288,000
$1.25 P/Share
|
|
Sep 19
2025
|
Simon H Stertzer Director |
BUY
Open market or private purchase
|
Indirect |
398,400
+40.26%
|
$398,400
$1.25 P/Share
|
|
Aug 22
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
700
+0.41%
|
$700
$1.83 P/Share
|
|
Aug 13
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
100
+0.06%
|
$100
$1.83 P/Share
|
|
Aug 12
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
400
+0.24%
|
$400
$1.75 P/Share
|
|
Aug 11
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
1,700
+1.0%
|
$1,700
$1.76 P/Share
|
|
Jun 30
2025
|
Andrew Scott Blank Director |
BUY
Open market or private purchase
|
Indirect |
72,289
+17.28%
|
$144,578
$2.08 P/Share
|
|
Jun 30
2025
|
Simon H Stertzer Director |
BUY
Open market or private purchase
|
Indirect |
72,289
+27.28%
|
$144,578
$2.08 P/Share
|
|
Jun 30
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
24,096
+12.68%
|
$48,192
$2.08 P/Share
|
|
Jun 30
2025
|
David Mc Clung Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,819
+9.13%
|
$9,638
$2.08 P/Share
|
|
May 30
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
100
+0.07%
|
$200
$2.21 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.26M shares |
|---|---|
| Grant, award, or other acquisition | 203K shares |
| Payment of exercise price or tax liability | 101K shares |